Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 51

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part II, Item 1A
Chunk 51
---
In
addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed
in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025,
which is available at www.sec.gov. Any of the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended December
31, 2024 could materially affect our business, financial condition or future results, and such risk factors may not be the only risks
we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially
adversely affect our business, financial condition or future results. We do not undertake to update any of the “forward-looking”
statements or to announce the results of any revisions to these “forward-looking” statements except as required by law.

ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On
April 23, 2025, the Company issued 25,000 shares of its common stock to a marketing firm and 78,816 shares of its common stock to an
investor relations firm for services rendered under consulting agreements. The shares were issued
with an aggregate grant date fair value of $66,000. The shares issued to these consultants are restricted and bear a Rule 144
legend.

On
June 10, 2025, the Company approved the grant of 250,000 options pursuant to the Company’s 2023 Equity Incentive Plan to a consultant
for services to be rendered under a consulting agreement. The exercise price of the options is $0.67 per share, with 25% of the options
vesting immediately and the remainder vesting ratably on a monthly basis, commencing on July 31, 2025 and ending on May 31, 2027. The
options expire ten years after the grant date.

All
of these transactions described above were exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as
amended, as transaction by an issuer not involving a public offering. The purchasers of securities in each of these transactions represented
their intention to acquire the securities for investment only and not with a view to offer or sell, in connection with any distribution
of